A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
Running, not enrolling · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.
Key facts
- Study ID
- NCT06880549
- Run by
- ModernaTX, Inc.
- People needed
- 42
- Starts
- 2025-03-25
- Expected to finish
- 2027-08-03
- Last updated by the study team
- 2026-05-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- START Midwest — Grand Rapids, Michigan, United States
- START San Antonio — San Antonio, Texas, United States
- START Mountain Region — West Valley City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.